Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pharmacotherapy for the treatment of depression in patients with alzheimer’s disease: a treatment-resistant depressive disorder
Madia Lozupone, Maddalena La Montagna, Francesca D’Urso, et al.
Expert Opinion on Pharmacotherapy (2018) Vol. 19, Iss. 8, pp. 823-842
Closed Access | Times Cited: 47

Showing 1-25 of 47 citing articles:

Extrasynaptic NMDA receptors in acute and chronic excitotoxicity: implications for preventive treatments of ischemic stroke and late-onset Alzheimer’s disease
Shan Ping Yu, Michael Qize Jiang, Seong S. Shim, et al.
Molecular Neurodegeneration (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 54
Development of disease-modifying drugs for frontotemporal dementia spectrum disorders
Francesco Panza, Madia Lozupone, Davide Seripa, et al.
Nature Reviews Neurology (2020) Vol. 16, Iss. 4, pp. 213-228
Closed Access | Times Cited: 96
Depression in Alzheimer's Disease: A Delphi Consensus on Etiology, Risk Factors, and Clinical Management
Luis Agüera‐Ortiz, R. García-Ramos, Francisco J. Grandas Pérez, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 58
Active constituents of saffron (Crocus sativus L.) and their prospects in treating neurodegenerative diseases (Review)
Weijing Yang, Xue Qiu, Qinghua Wu, et al.
Experimental and Therapeutic Medicine (2023) Vol. 25, Iss. 5
Open Access | Times Cited: 27
Converged avenues: depression and Alzheimer’s disease– shared pathophysiology and novel therapeutics
Shivanshu Bajaj, Radhakrishnan Mahesh
Molecular Biology Reports (2024) Vol. 51, Iss. 1
Closed Access | Times Cited: 7
Pharmacological Treatment of Depression in Alzheimer’s Disease: A Challenging Task
Tommaso Cassano, Silvio Calcagnini, Antonio Carbone, et al.
Frontiers in Pharmacology (2019) Vol. 10
Open Access | Times Cited: 46
Antioxidant Activity of Fluoxetine and Vortioxetine in a Non-Transgenic Animal Model of Alzheimer’s Disease
Giuseppe Caruso, Margherita Grasso, Annamaria Fidilio, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 35
Does the application of acetylcholinesterase inhibitors in the treatment of Alzheimer’s disease lead to depression?
Miloš Mitić, Tamara Lazarević‐Pašti
Expert Opinion on Drug Metabolism & Toxicology (2021) Vol. 17, Iss. 7, pp. 841-856
Closed Access | Times Cited: 34
The Possible Application of Ketamine in the Treatment of Depression in Alzheimer’s Disease
Islam Mohammad Shehata, Waniyah Masood, Nouran Ehab Nemr, et al.
Neurology International (2022) Vol. 14, Iss. 2, pp. 310-321
Open Access | Times Cited: 24
Overview of treatment-resistant depression
Cheng‐Ta Li
Progress in brain research (2023), pp. 1-23
Closed Access | Times Cited: 15
Treatment resistant late-life depression: A narrative review of psychosocial risk factors, non-pharmacological interventions, and the role of clinical phenotyping
Regan Patrick, Rebecca A. Dickinson, Melanie T. Gentry, et al.
Journal of Affective Disorders (2024) Vol. 356, pp. 145-154
Closed Access | Times Cited: 5
Depression in Alzheimer’s Disease: An Alternative Role for Selective Serotonin Reuptake Inhibitors?
Richard J. Elsworthy, Sarah Aldred
Journal of Alzheimer s Disease (2019) Vol. 69, Iss. 3, pp. 651-661
Open Access | Times Cited: 42
Efficacy of antidepressant drugs in the treatment of depression in Alzheimer disease patients: A systematic review and network meta-analysis
Yanhong He, Hao Li, Jinbo Huang, et al.
Journal of Psychopharmacology (2021) Vol. 35, Iss. 8, pp. 901-909
Closed Access | Times Cited: 30
Antidepressants in Alzheimer’s Disease: A Focus on the Role of Mirtazapine
Ana Salomé Correia, Nuno Vale
Pharmaceuticals (2021) Vol. 14, Iss. 9, pp. 930-930
Open Access | Times Cited: 29
Use of vortioxetine in different neurological fields: a systematic review and future perspectives
Giulio Verrienti, Isabella Colonna, Cecilia Raccagni
Neurological Sciences (2025)
Closed Access
Amygdala: Neuroanatomical and Morphophysiological Features in Terms of Neurological and Neurodegenerative Diseases
Vladimir N. Nikolenko, Marine V. Oganesyan, N. A. Rizaeva, et al.
Brain Sciences (2020) Vol. 10, Iss. 8, pp. 502-502
Open Access | Times Cited: 32
Drugs targeting APOE4 that regulate beta‐amyloid aggregation in the brain: Therapeutic potential for Alzheimer's disease
Joan Poblano, Ileana Castillo‐Tobías, Lia Berlanga, et al.
Basic & Clinical Pharmacology & Toxicology (2024) Vol. 135, Iss. 3, pp. 237-249
Closed Access | Times Cited: 3
Frontotemporal dementia
Shaimaa Nasr Amin, Ahmed Bassam Mohd, Carla Ammar Samain, et al.
Elsevier eBooks (2024), pp. 131-146
Closed Access | Times Cited: 2
Abnormal changes in functional connectivity between the amygdala and frontal regions are associated with depression in Alzheimer’s disease
Zhongwei Guo, Xiaozheng Liu, Songquan Xu, et al.
Neuroradiology (2018) Vol. 60, Iss. 12, pp. 1315-1322
Closed Access | Times Cited: 22
Promising therapies for the treatment of frontotemporal dementia clinical phenotypes: from symptomatic to disease-modifying drugs
Giancarlo Logroscino, Bruno P. Imbimbo, Madia Lozupone, et al.
Expert Opinion on Pharmacotherapy (2019) Vol. 20, Iss. 9, pp. 1091-1107
Closed Access | Times Cited: 22
Ketamine: A Neglected Therapy for Alzheimer Disease
Neil R. Smalheiser
Frontiers in Aging Neuroscience (2019) Vol. 11
Open Access | Times Cited: 21
Association Between the Cholinesterase Inhibitor Donepezil and the Cholinergic Precursor Choline Alphoscerate in the Treatment of Depression in Patients with Alzheimer’s Disease
Anna Carotenuto, Angiola Maria Fasanaro, Valentino Manzo, et al.
Journal of Alzheimer s Disease Reports (2022) Vol. 6, Iss. 1, pp. 235-243
Open Access | Times Cited: 11
Treatment resistant depression in elderly
Sheng-Chiang Wang, Jennifer S. Yokoyama, Nian‐Sheng Tzeng, et al.
Progress in brain research (2023), pp. 25-53
Closed Access | Times Cited: 6
Ketamine exerts dual effects on the apoptosis of primary cultured hippocampal neurons from fetal rats in vitro
Guo-Hua Wu, Que-Hui Guo, Xiao-Dong Xu, et al.
Metabolic Brain Disease (2023) Vol. 38, Iss. 7, pp. 2417-2426
Closed Access | Times Cited: 6
Differences in Cerebral Structure Associated With Depressive Symptoms in the Elderly With Alzheimer’s Disease
Yue Wu, Xingqi Wu, Qiang Wei, et al.
Frontiers in Aging Neuroscience (2020) Vol. 12
Open Access | Times Cited: 16
Page 1 - Next Page

Scroll to top